Home
About
Overview
Sharing Data
ORCID
Help
History (27)
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500?mg/m(2) every 21 days in patients with cancer.
Validation of a certified nurse-midwifery database for use in quality monitoring and outcomes research.
G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates.
CpG DNA is an effective oral adjuvant to protein antigens in mice.
Controlling transcription in human pluripotent stem cells using CRISPR-effectors.
See All 27 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Controlling transcription in human pluripotent stem cells using CRISPR-effectors.
Genga RM, Kearns NA, Maehr R. Controlling transcription in human pluripotent stem cells using CRISPR-effectors. Methods. 2016 May 15; 101:36-42.
View in:
PubMed
subject areas
Animals
Base Sequence
Cell Culture Techniques
CRISPR-Cas Systems
HEK293 Cells
Humans
Pluripotent Stem Cells
Transcription, Genetic
authors with profiles
Rene Maehr PhD